SLXP Share Price

Open 172.72 Change Price %
High 172.96 1 Day 0.16 0.09
Low 172.71 1 Week 0.00 0.00
Close 172.81 1 Month 0.00 0.00
Volume 4298146 1 Year 0.00 0.00
52 Week High 21.48
52 Week Low 0.00
SLXP Important Levels
Resistance 2 173.04
Resistance 1 172.95
Pivot 172.83
Support 1 172.67
Support 2 172.58
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP)

SLXP Technical Analysis 5
As on 31st Mar 2015 SLXP Share Price closed @ 172.81 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 132.17 & Strong Buy for SHORT-TERM with Stoploss of 150.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
SLXP Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
SLXP Other Details
Segment EQ
Market Capital 2245779712.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
SLXP Address
SLXP
N/A
SLXP Latest News
Valeant Pharmaceuticals Intl Inc (VRX) To Retain Salix Pharmaceuticals, Ltd ...   Insider Monkey (blog)   - 01st Dec 16
Valeant, in Push for Cash, Looks to Sell Stomach-Drug Business   Wall Street Journal   - 02nd Nov 16
SEC investigating former Salix Pharma execs, Reuters reports   Triangle Business Journal   - 10th Feb 16
Valeant Pharmaceuticals International, Inc. Completes Tender Offer For Salix ...   PR Newswire (press release)   - 01st Apr 15
Salix Pharmaceuticals Ltd: Here's Why Valeant Fought So Hard To Acquire Salix   International Business Times   - 17th Mar 15
Salix Pharmaceuticals Reports 4Q2014 and FY2014 Results   Business Wire (press release)   - 03rd Mar 15
Valeant To Acquire Salix Pharmaceuticals For $158.00 Per Share In Cash   PR Newswire (press release)   - 23rd Feb 15
Salix Pharmaceuticals CEO Plans to Retire   Wall Street Journal   - 06th Jan 15
Why Salix Pharmaceuticals, Ltd. Stock Was Clobbered in November   Motley Fool   - 05th Dec 14
Tougher US Tax Rules Cited as Salix Ends Cosmo Deal   Bloomberg   - 03rd Oct 14
Interactive Technical Analysis Chart Salix Pharmaceuticals, Ltd. ( SLXP NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Salix Pharmaceuticals, Ltd.
SLXP Business Profile
Salix Pharmaceuticals, Ltd. is a specialty pharmaceutical company dedicated to acquiring, developing and commercializing prescription drugs and medical devices used in the treatment of a variety of gastrointestinal disorders, which are those affecting the digestive tract. As of December 31, 2012, the Company�s products included XIFAXAN, MOVIPREP, APRISO, RELISTOR, OSMOPREP, SOLESTA, DEFLUX, FULYZAQ, GIAZO, METOZOLV ODT, AZASAN, ANUSOL-HC, PROCTOCORT, PEPCID, DIURIL and COLAZAL. As of December 31, 2012, its primary product candidates under development included Rifaximin, Methylnaltrexone bromide oral, Budesonide foam and Rifaximin EIR. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc. In January 2014, Salix Pharmaceuticals, Ltd. acquired Santarus, Inc.